A norovirus vaccine would likely be offered first to people aged 65 years and older as well as immunocompromised people, given that norovirus infections tend to be much worse for these groups, ...

Norovirus is surging across the U.S., with case numbers higher now than they've been at the same time in more than a decade, according to the U.S. Centers for Disease Control and Prevention (CDC ...

The participants were randomly assigned to get either a placebo (22) or a low (16), medium (16), or high (11) dose of the vaccine VXA-G1.1-NN, which targets one genotype of norovirus. Again, the ...

How close are we to having a norovirus vaccine? Moderna is currently enrolling 25,000 people around the world in a phase 3 trial of the shot, after earlier testing showed encouraging results.

How close are we to having a norovirus vaccine? Moderna is currently enrolling 25,000 people around the world in a phase 3 trial of the shot, after earlier testing showed encouraging results.

Despite millions of cases of norovirus in the U.S. each year—and a current surge in outbreaks—there is still no vaccine for the stomach bug. Here's why it's taking so long, and how close we ...

He told IDWeek attendees that the vaccine contains three mRNAs that encode for the major capsid protein 1 (VP1) of three globally prevalent norovirus genotypes -- GII.4, GI.3, and GII.3.

Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection. npj Vaccines. Published online October 1, 2024. doi: 10.1038/s41541-024-00976-z.

The early vaccines were crude and the outcomes has been universally dismal. This could change if Moderna hits the mark with mRNA-1403, its experimental mRNA-based norovirus vaccine. More on this later ...

While this vaccine candidate, now named HIL-216, is also a VLP, it offers a broader scope. HIL-216 addresses six groups of norovirus viral strains, including the two covered by HIL-214.

There are vaccines for norovirus under study. One vaccine by the biotech company HilleVax failed in 2024 to prove its effectiveness in a clinical trial of infants.